ResMed Inc. (RMD) SEC Filings & Earnings Calls

GLP-1 drug competition risk

“the uncertainty associated with the introduction of new medications for weight loss cleared for use by patients with obesity and obstructive sleep apnea”

Stock price decline impacting executive compensation and retention

“Our stock price performance over the 2026 fiscal year from $258.00 on June 30, 2025 to $194.88 on June 30, 2026 eroded stockholder value” · word for word

Auditor change may signal increased scrutiny or desire for fresh perspective, but no disagreements indicate low risk.

“No disagreements or reportable events with KPMG; competitive review process.”

Supply Chain Disruptions

“disruptions and delays in the supply chain” · word for word

Regulatory Changes

“changes or developments in healthcare reform, social, macroeconomic, market, legal or regulatory circumstances” · word for word

Foreign exchange exposure; constant currency growth 8% vs reported 9%.

“up 8% on a constant currency basis.” · word for word

MatrixCare divestiture execution risk.

“Announced agreement to sell MatrixCare business; transaction expected to close during Q1 FY2027.” · word for word

Transaction subject to regulatory approvals and customary closing conditions; expected close in Q1 FY2027.

“Subject to required regulatory approvals and customary closing conditions.” · word for word

Stranded costs from divestiture largely offset by TSAs in first year; remaining costs to be mitigated over time.

“TSAs will largely offset stranded costs in the first-year post-closing.” · word for word

Equity Investment Volatility

“Gain (loss) on equity investments ($10,130k) loss in Q3 2026 vs ($5,647k) loss in Q3 2025.”

Foreign Exchange Exposure

“Foreign currency translation gain (loss) adjustments $15,361k in Q3 2026 vs $71,742k in Q3 2025.”

SG&A expenses increased 11% constant currency, partly from VirtuOx acquisition and strategic evaluation costs

“Selling, general, and administrative expenses increased by 11 percent on a constant currency basis” · word for word

Restructuring expenses

“Restructuring expenses $5,935 (Q2 FY2026) and $21,745 (six months)”

Foreign currency translation risk

“Foreign currency translation gain (loss) adjustments $30,545 (Q2 FY2026) vs ($210,410) (prior year Q2)”

Restructuring charges from workforce planning may indicate ongoing cost optimization but could signal operational disruption.

“We recorded $6 million of restructuring-related charges following the finalization of our company-wide workforce planning activities undertaken in the first quarter of the fiscal year.” · word for word

Potential dilution from increased shares under stock plans.

“2.4M shares added to incentive plan; 3M shares added to ESPP.”

Patent Litigation Exposure

“On June 2, 2021, New York University, or NYU, filed a complaint for patent infringement... On June 16, 2022, Cleveland Medical Devices Inc., or Cleveland Medical, filed suit for patent infringement against Resmed...” · word for word

Restructuring Execution Risk

“Restructuring expenses $15,810 vs $0 YoY”

Foreign Exchange Exposure

“Foreign currency translation gain (loss) adjustments $12,380 vs $141,176 YoY”

Restructuring charges of $16 million related to workforce planning aligned with 2030 strategic priorities.

“We recorded $16 million of restructuring-related charges following company-wide workforce planning activities” · word for word

Foreign currency fluctuations had adverse effect on reported results; constant currency revenue growth 8% vs reported 9%.

“Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis” · word for word